LTI-214 / Leukogene Therap - LARVOL DELTA

MHC class II engager immunotherapy for the treatment of acute myeloid leukemia (AACR 2026) - "However, while ~90% of AML cases express CD33, 50% of these patients harbor a single nucleotide polymorphism (SNP) that eliminates the antibody binding epitope for existing CD33-targeted antibody therapeutics such as gemtuzumab ozogamicin (Mylotarg®)... These experiments demonstrate the potential of LTI-214 in AML and emphasize the importance and targetability of MHCII in cancer immunotherapy."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD4 • CD8 • HLA-DRB1 • PD-L1

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia. (PubMed, Blood Cancer J) - "Finally, M2T-CD33 was enhanced by combinations with anti-PD-1 therapy. These experiments demonstrate the preclinical potential of M2T-CD33 in AML and emphasize the importance of MHCII for cancer immunotherapy."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD4 • CD8

U.S. FDA Grants Orphan Drug Designation to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the Treatment of Acute Myeloid Leukemia (Businesswire)

Orphan drug • Acute Myelogenous Leukemia